Mission shrnas in the plko 1 vector

M3, M6, M8, M10, and M12 primary meningioma cells were cultured in Neurobasal Medium (Thermo Fisher Scientific) supplemented with EGF and FGF (Sigma-Aldrich), B27 and N2 (Thermo Fisher Scientific), glutamine, and 5% fetal bovine serum (Table S8). BEN-MEN-1 and HBL-52 primary meningioma cells were cultured in Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific) supplemented with 10% newborn calf serum and glutamine (Mei et al., 2017 (link)). FOXM1 and CTNNB1 constructs in the pCMV6-Entry vector were obtained from OriGene (Rockville, MD) and transfected using Lipofectamine LTX with Plus Reagent (Thermo Fisher Scientific). Mission shRNAs in the pLKO.1 vector were obtained from Sigma-Aldrich and transduced using lentivirus particles (Table S8). FDI-6 was obtained from Sigma-Aldrich and reconstituted in DMSO. All experiments were performed 72 hr after transfection, transduction, or initiation of pharmacologic treatment. Proliferation assays were performed using the Cell Titer 96 Non-Radioactive Cell Proliferation Assay Kit and a GloMax Discovery Multimode Microplate Reader (Promega).